ELVN
Enliven Therapeutics Inc

1,244
Loading...
Loading...
News
all
press releases
How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%
The consensus price target hints at a 102.4% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·10d ago
News Placeholder
More News
News Placeholder
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 75.7% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·2mo ago
News Placeholder
Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’
Ortex data shows short interest in Enliven Therapeutics had hovered between 24% and 29% since October 2023.
Stocktwits·2mo ago
News Placeholder
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference PR Newswire BOULDER, Colo., Feb...
PR Newswire·6mo ago
News Placeholder
Mizuho refreshes its US top picks list for January
Investing.com -- Mizuho (NYSE:MFG) has updated its US Top Picks list for January, adding Chewy (NYSE:CHWY), GE Vernova (NYSE:GEV), Enliven Therapeutics Inc (NASDAQ:ELVN), Quest Diagnostics (NYSE:DGX), DuPont de Nemours (NYSE:DD), and Salesforce (NYSE:CRM). These selections reflect Mizuho’s highest-conviction ideas driven by catalysts expected to play out over the next 12 months.
investing.com·8mo ago
News Placeholder
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update PR Newswire...
PR Newswire·10mo ago
News Placeholder
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference Enliven Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire BOULDER, Colo., Nov. 7, 2024...
PR Newswire·10mo ago
News Placeholder
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket PR Newswire VANCOUVER, BC, Oct. 4, 2024 USA News Group...
PR Newswire·11mo ago
News Placeholder
Enliven Therapeutics: A Strong Buy on Promising CML Treatments and Market Potential
Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Enliven Therapeutics (ELVN Research Report). The associated price targ...
TipRanks Financial Blog·1y ago
News Placeholder
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday's session. read more...
Benzinga·1y ago

Latest ELVN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.